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The estrogen receptor b (ERb) is emerging as an important
player in the physiology of the endocrine pancreas. We evaluated
the role and antidiabetic actions of the ERb selective agonist
WAY200070 as an insulinotropic molecule. We demonstrate that
WAY200070 enhances glucose-stimulated insulin secretion both
in mouse and human islets. In vivo experiments showed that
a single administration of WAY200070 leads to an increase in
plasma insulin levels with a concomitant improved response to
a glucose load. Two-week treatment administration increased
glucose-induced insulin release and pancreatic b-cell mass and
improved glucose and insulin sensitivity. In addition, streptozoto-
cin-nicotinamide–induced diabetic mice treated with WAY200070
exhibited a signiﬁcant improvement in plasma insulin levels and
glucose tolerance as well as a regeneration of pancreatic b-cell
mass. Studies performed in db/db mice demonstrated that this
compound restored ﬁrst-phase insulin secretion and enhanced
pancreatic b-cell mass. We conclude that ERb agonists should
be considered as new targets for the treatment of diabetes.
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Diabetes has become one of the most challenginghealth problems on a global scale, with an es-timated 285 million people affected by this dis-ease in 2010 (1,2). The most common form of
diabetes is type 2 (T2D), which results from the interaction
of a subject’s genetic background with the environment.
Both insulin resistance and pancreatic b-cell dysfunction
contribute importantly to the pathogenesis of this disease;
however, T2D develops only when insulin secretion can-
not meet the insulin demand (3–5). Therefore, the most
effective therapy for T2D should control not only b-cell
failure, but also the loss of b-cell mass. Today, although
there is an extensive range of oral antidiabetic drugs that
differ in their modes of action, none seem to be completely
effective (6–9).
Estrogen receptors are emerging as important mole-
cules involved in modulating pancreatic b-cell function.
17b-estradiol (E2) modulates insulin content in an estro-
gen receptor a (ERa)-dependent manner (10). In addition,
the activation of the estrogen receptor b (ERb) triggers the
closure of ATP-sensitive K+ (KATP) channels, enhancing
glucose-induced [Ca2+] oscillations and insulin release
cooperatively with glucose (11). Selective ERb agonists,
such as diarylpropionitrile (DPN), elicit this rapid phenom-
enon (1–7 min). The KATP channel–dependent pathway in
the pancreatic b-cell is the major trigger for glucose-
stimulated insulin secretion (GSIS). Accordingly, the fact
that ERb selective ligands can activate this mechanism
raises the possibility that these compounds may behave as
rapid insulinotropic agents and, thus, lead to new antidi-
abetic drugs.
Since the discovery of ERb in the mid-1990s, intense
research efforts continue to focus on the biology of this
receptor and on developing and evaluating the use of ERb-
speciﬁc agonists in animal models of human disease. Re-
markably, some of the ERb agonists are already under
evaluation in clinical studies (12–14). At present, ERb is
a promising novel drug target for the treatment of cancer
and multiple sclerosis because of distinct functional
characteristics of this estrogen receptor subtype.
Here, we evaluate the action of a selective ERb agonist
(WAY200070) on glucose homeostasis in different animal
models of diabetes. We analyze the capacity of this com-
pound to normalize fasting glucose levels, to enhance en-
dogenous insulin secretion, and to regulate b-cell mass.
We hypothesize that the use of selective ERb agonists
offers great hope in the treatment of T2D.
RESEARCH DESIGN AND METHODS
Animals. Adult male C57BL/6 mice aged 3–4 months were used. C57BL/6
(a globally standardized model) and db/db mice were obtained from Harlan
Laboratories (Barcelona, Spain). ERb knockout (BERKO) mice were gener-
ated as described in Krege et al. (15) and supplied by Dr. Gustafsson’s labo-
ratory. Streptozotocin-nicotinamide (STZ-NA) diabetic mice were used, which
is a model of moderate hyperglycemia combined with the loss of early phase
insulin secretion (16,17). WAY200070 (Tocris Cookson Ltd, Bristol, U.K.) was
injected intraperitoneally in a volume of 100 mL saline solution.
Islet and islet cell isolation. Pancreatic islets of Langerhans were isolated
by collagenase (Sigma, Madrid, Spain) digestion as previously described (18).
Freshly isolated islets were used for calcium and insulin secretion measure-
ments after a 2-h recovery. For experiments using isolated b-cells, islets were
dispersed into single cells with trypsin as previously described (19).
Recording intracellular calcium concentration. Freshly isolated pancreatic
islets of Langerhans were loaded with 5 mmol/L Fura-2 acetoxymethyl ester
(Molecular Probes, Invitrogen, Barcelona, Spain) for at least 1 h at room
temperature. Calcium recordings were obtained as previously described (20).
Insulin secretion measurements. Groups of ﬁve mouse islets were trans-
ferred to 400 mL of a buffer solution containing 140 mmol/L NaCl, 4.5 mmol/L
KCl, 2.5 mmol/L CaCl2, 1 mmol/L MgCl2, 20 mmol/L HEPES, and the corre-
sponding glucose concentration with ﬁnal pH of 7.4. Afterward, 100 mL cor-
responding buffer solution with 5% BSA was added and cooled down for
15 min on ice. The medium was then collected, and insulin was measured in
duplicate samples by radioimmunoassay with a Coat-A-Count kit (Siemens,
Los Angeles, CA). Protein concentration was measured by the Bradford dye
method (21).
Isolated human pancreatic islets from a nondiabetic male were provided by
the Nordic Network for Clinical Islet Transplantation (Prof. Olle Korsgren,
Uppsala University, Uppsala, Sweden). All procedures were approved by the
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ethical committees at Uppsala and Lund Universities. The islets were cultured
as previously described (22). The secreted insulin was measured with a ra-
dioimmunoassay kit (Millipore).
Patch clamp recordings. KATP channel activity was recorded using standard
patch clamp recording procedures from isolated pancreatic b-cells as pre-
viously described (22).
Glucose and insulin tolerance test. For intraperitoneal glucose tolerance
tests (IGTTs), animals were fasted overnight for 12 h, and blood samples were
taken from the tail vein. Animals were then injected intraperitoneally with 2 g/kg
glucose, and blood samples were taken at the indicated intervals. In STZ-NA and
db/db mice, the glucose load was 1.5 g/kg.
For intraperitoneal insulin tolerance tests, fed animals were used. Animals
were injected intraperitoneally with 0.75 IU/kg soluble insulin. The db/db mice
were fasted for 6 h and injected with 1.25 IU/kg soluble insulin. Blood glucose
was measured in each sample using an Accu-Chek compact glucometer (Roche,
Madrid, Spain).
Immunohistochemistry and b-cell mass. Pancreas samples were removed
and ﬁxed overnight in 4% paraformaldehyde. Subsequently, pancreatic tissue
was embedded in parafﬁn, and sections were prepared. After dehydration, the
sections were heated to 100°C in the presence of 10 mmol/L citrate buffer (pH
6.0) for 20 min. Endogenous peroxidase was blocked by incubation for 30 min
with a solution of 3% hydrogen peroxidase in 50% methanol. To block non-
speciﬁc binding, the sections were incubated in 3% BSA in PBS for 1 h at room
temperature. Tissue sections were then stained for b-cells with a rabbit anti-
human insulin antibody (1:100) (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) overnight at 4°C. The sections were incubated with the secondary anti-
body biotinylated anti-rabbit IgG (H+L) (Vector Laboratories, Burlingame,
CA). The Vectastain ABC kit (Vector Laboratories) was used for the avidin-biotin
complex method. Peroxidase activity was visualized with 3,39-diaminobenzidine
(Dako, Barcelona, Spain). The sections were lightly counterstained with hema-
toxylin. The islet cross-sectional area and the total pancreatic area were mea-
sured using MetaMorph Software. At least two sections, separated by 200 mm,
were measured per animal.
b-Cell replication.Micewere injected intraperitoneally with 100mg/g BrdU 6 h
before being killed. Pancreatic tissue was collected, ﬁxed, and processed as just
described. Samples were then incubated with antibodies for insulin (1:100
rabbit polyclonal; Santa Cruz Biotechnology, Madrid, Spain) and BrdU (1:100
monoclonal; Dako) overnight at 4°C. After incubation with secondary anti-
bodies, sections were mounted using ProLong Gold Antifade Reagent
(Invitrogen).
Measurement of the b-cell proliferation rate in vitro. Single islets cells
were cultured for 48 h in the presence of 10 mmol/L BrdU (Sigma) and the
vehicle or WAY200070. They were then ﬁxed for 5 min with 4% para-
formaldehyde, washed with PBS, and made permeable with 1% Triton X-100.
Nonspeciﬁc interactions were blocked with PBS plus 5% normal goat serum
for 1 h. Cells were then incubated with the primary antibody rabbit anti-human
insulin antibody (1:100) (Santa Cruz Biotechnology, Inc.) overnight at 4°C. As
a secondary antibody, goat anti-rabbit Alexa Fluor 546 was used at 1/500 for
1 h at room temperature. After this, cells were ﬁxed again and washed with
PBS. The cells were then treated with 2 mol/L HCl for 20 min at 37°C and
washed with 0.1 mol/L Na2B4O7 (pH 8.5). To detect BrdU, the mouse anti-BrdU
antibody (M0744; Dako) at 1/100 was used overnight at 4°C along with goat
anti-mouse Alexa Fluor 488. The nuclei were stained with 1 mmol/L DAPI for
15 min at room temperature.
Plasma analysis. Insulin was measured by ELISA (Mercodia, Uppsala, Swe-
den, and Crystal Chem, Downers Grove, IL) and leptin was measured by ELISA
(Crystal Chem, Downers Grove, IL). Triglyceride and glycerol levels were
measured with the GTO-Trinder Triglycerides assay (Sigma).
Statistical analysis. Data are expressed as mean 6 SEM. Statistical analysis
was performed using Student t test or one-way ANOVA, as indicated
(SigmaStat 3.1 software; Systat Software, Inc., Chicago, IL). P , 0.05 was
considered signiﬁcant.
Study approval. All animal experiments were performed in accordance with
national and institutional guidelines for animal care. The ethical committee of
Miguel Hernandez University of Elche (Comisión de Ética en la Investigación
Experimental) reviewed and approved the method used (Approval ID Number
IB-ARL-002-12).
RESULTS
In vitro experiments performed with isolated pancreatic
b-cells from mice showed that WAY200070 (100 pmol/L)
decreased KATP channel activity (Fig. 1A). In whole mouse
islets of Langerhans, the agonist promoted both a greater
global intracellular Ca2+ entry (Fig. 1B) and an increase
of insulin secretion in response to glucose stimulation
(8 mmol/L glucose) (Fig. 1C). WAY200070 at 100 pmol/L en-
hanced GSIS in the presence of 8 and 16 mmol/L glucose
but, of interest, it did not have any effect when applied in
the presence of low glucose concentrations (3 mmol/L)
(Fig. 1D). The effect of WAY200070 on GSIS of human
islets was also analyzed. Insulin release was enhanced in
a dose-dependent manner, with a maximal effect at a dose
of 100 nmol/L (Fig. 1E).
We next studied the in vivo effect of WAY200070. For this
purpose, we used male C57BL/6 mice aged 3 months. Fasted
animals were injected intraperitoneally with 2 g/kg glucose
followed by the intraperitoneal administration of a vehicle or
WAY200070 at different concentrations (3, 10, or 30 mg/kg).
As shown in Figure 2A, glucose sensitivity was improved in
those animals that received the agonist WAY200070, espe-
cially at a concentration of 10 mg/kg (W10) and 30 mg/kg
(W30), although the effects were not statistically signiﬁcant
at the latter dose. When plasma insulin levels were mea-
sured at 30 min, a higher glucose-stimulated insulin release
was observed at W10 compared with the vehicle-treated
group (Fig. 2B). Under fasting conditions, no changes of
glycemia were observed in animals treated with the ERb
agonist at any concentration assayed (Fig. 2C).
To unequivocally demonstrate that the in vivo insulino-
tropic effect of WAY200070 is an ERb-mediated effect, we
compared its action in wild type (WT) and ERb knockout
(BERKO) mice. A single administration of W10 in WT mice
resulted in a lower rise of glycemia levels in response to
a glucose challenge, indicating that these mice tolerated
glucose better than WT vehicle-treated mice (Fig. 2D).
However, when the same experiment was performed in
BERKO mice, no differences were observed between ve-
hicle and ERb agonist-treated animals (Fig. 2E). When we
measured plasma insulin levels 30 min after a glucose load,
we observed a higher glucose-stimulated insulin release in
the WT mice that had received a single dose of W10 (Fig.
2F) but no changes in the BERKO mice (Fig. 2F).
We studied the extent to which an ERb agonist can be
a positive modulator of energy balance and glucose ho-
meostasis under healthy conditions. For this purpose, we
analyzed glucose and insulin sensitivity in C57BL/6 male
mice treated with W10 for 14 days. The treatment with the
agonist was found to improve glucose tolerance (Fig. 3A)
and increase the glucose-stimulated in vivo insulin release
30 min after the glucose load (1.41 6 0.19-fold increase
over basal insulin levels in vehicle-treated mice versus
2.01 6 0.16-fold increase in W10-treated mice) (Fig. 3B),
suggesting that the pancreatic b-cells were working more
vigorously. A slightly better insulin sensitivity was also
observed in these animals compared with the controls
(Supplementary Fig. 1A). In addition to this, b-cell mass
and islet size were higher in W10-treated mice compared
with the vehicle-treated mice (Fig. 3C and D). We studied
whether the augmented b-cell mass was a result of an in-
creased b-cell proliferation. We performed coimmuno-
staining for insulin and BrdU and found that animals
treated with the ERb agonist exhibited a larger number of
proliferating b-cells (Fig. 3E). Dispersed islet cells were
treated with a range of doses of this compound for 2 days,
and b-cell proliferation was quantiﬁed by using BrdU in-
corporation over the same period. We observed a signiﬁ-
cant increase in pancreatic b-cell proliferation in the ERb
agonist–treated cultures, which suggests that the activa-
tion of ERb signaling directly affects pancreatic b-cell
replication (Fig. 3F).
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FIG. 1. In vitro exposure to an ERb agonist (WAY200070) induced reduction of KATP channel activity and enhanced glucose-induced intracellular
calcium concentration signals and insulin secretion. A: WAY200070 100 pmol/L decreased KATP channel activity in isolated pancreatic b-cells from mice
(n = 6). B: This was accompanied by a greater increase in global intracellular Ca2+ entry after glucose stimulation (n = 6), as indicated by a greater AUC
(inset). C: Insulin release in response to 8 mmol/L glucose, 8 mmol/L glucose and DPN (1 nmol/L), and 8 mmol/L glucose and WAY200070 (100 pmol/L,
1 nmol/L, and 10 nmol/L) was measured in intact mouse islets of Langerhans. Insulin levels were signiﬁcantly higher in the presence of WAY200070 (n =
8). D: WAY200070-induced insulin secretion from mouse islets exposed to 3, 8, and 16 mmol/L glucose for 1 h (n = 8). WAY200070 was applied at 100
pmol/L. Note that WAY200070 action was signiﬁcant only when stimulatory glucose concentrations were used.E: Insulin release in response to 8 mmol/L
glucose, 8 mmol/L glucose and DPN (1 nmol/L), and 8 mmol/L glucose and WAY200070 (100 pmol/L, 1 nmol/L, and 100 nmol/L) was measured in intact
human islets of Langerhans. Data are mean 6 SE. *P < 0.05, ***P < 0.001 versus control (Student t test). Statistical analyses between groups in C, D,
and E were evaluated by one-way ANOVA, with P < 0.05 considered signiﬁcant. G, glucose; W, WAY200070.
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We also observed clear hyperinsulinemia in the fed state
(Fig. 4A) but no differences in leptin (Fig. 4B) or tri-
glyceride (Fig. 4C) levels, although glycerol levels were
decreased in the ERb agonist-treated group (Fig. 4D). Mild
diabetes was induced by administering a single dose of
STZ 150 mg/kg and NA 1,000 mg/kg. As shown in Figure
5A, 10 days after the STZ-NA treatment, these animals
exhibited moderate fasting hyperglycemia (vehicle-treated
control mice 90 6 4.31 mg/dL, STZ-NA diabetic mice 126 6
5.3 mg/dL, P , 0.05). An IGTT showed that STZ-NA mice
presented consistent glucose intolerance as indicated by
the bigger area under the curve (AUC) (Fig. 5A). At this
point, we divided STZ-NA mice into two groups: One re-
ceived an intraperitoneal injection of W10 for 7 days, and
the other received a vehicle injection for the same period.
The 1-week treatment provoked a decrease in fasting gly-
cemia levels in the diabetic mice treated with the ERb
agonist (control mice 108 6 2.36 mg/dL, diabetic mice
treated with WAY200070 109 6 4.03 mg/dL, diabetic mice
140 6 9.16 mg/dL, P , 0.05). We also observed from the
IGTT that glucose tolerance was signiﬁcantly improved in
the diabetic group treated with WAY200070, with similar
levels of glycemia as the control group (Fig. 5B). This
improvement in glucose sensitivity was accompanied by a
restoration of plasma insulin levels (Fig. 5C). Remarkably,
we found that pancreatic b-cell mass in diabetic mice
exhibited a clear decrease compared with that of controls,
whereas diabetic mice treated with the agonist presented
not only similar levels to the control mice (Fig. 5D), but
also similar islet size (Fig. 5E). The restoration of b-cell
mass is related to an increase of b-cell replication (Fig.
5F). No differences in the plasma leptin or triglyceride
levels were found between groups (Supplementary Fig. 1B
and C). A marked tendency for glycerol levels to decrease
was observed in the diabetic group treated with the ERb
agonist, although it was not statistically signiﬁcant (Sup-
plementary Fig. 1D).
At ;14 weeks of age, db/db mice presented hypergly-
cemia, glucose intolerance, and decreased in vivo insulin
secretion in response to a glucose load (Supplementary
Fig. 2A and B). At this moment, the animals were treated
with W10 for 14 days or with the vehicle.
FIG. 2. Single in vivo administration of the ERb agonist (WAY200070) improved glucose tolerance. A: Fasted C57BL/6 male mice were injected
intraperitoneally with a single dose of WAY200070 3 mg/kg (W3), 10 mg/kg (W10), or 30 mg/kg (W30). In parallel, they were administered a glucose
challenge (2 g/kg). Through an IGTT we observed an improvement in glucose response in animals treated with the ERb agonist at W10. Thus, the
AUC (inset) was signiﬁcantly reduced in this group (n = 5). B: In addition, we measured plasma insulin levels 30 min after the administration of the
glucose challenge and the ERb agonist and detected that glucose-stimulated insulin release was signiﬁcantly higher in W10 mice than in controls
(8–10 mice/group). C: In the fasted state, a single injection of WAY200070 did not have an effect on glucose sensitivity (5 mice/group). We con-
ﬁrmed that this ﬁnding was an ERb-mediated effect by using WT and BERKO mice. D: Fasted WT mice were injected intraperitoneally with a single
dose of W10 or vehicle in parallel with a glucose challenge of 2 g/kg. A better response to the glucose load was observed in the animals that received
the agonist, with a decreased AUC (inset) (5–7 mice/group). E: No changes in glucose tolerance or the AUC were observed in BERKO mice in
response to the agonist W10-treated mice compared with the vehicle-treated mice. F: Glucose-stimulated insulin release was clearly enhanced in
W10 WT mice but not in W10 BERKO mice (5–7 mice/group). Data are mean 6 SE. *P < 0.05 versus vehicle (Student t test). In A and C, statistical
analysis between groups was evaluated by one-way ANOVA, with P < 0.05 considered signiﬁcant. BERKO, ERb knockout.
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Glucose levels after overnight fasting were slightly re-
duced in W10 db/db mice (241 6 18.5 mg/dL) compared
with the vehicle db/db mice (303 6 31.5 mg/dL), although
differences were not signiﬁcant (P = 0.1). To explore dif-
ferences in glucose homeostasis, we performed an IGTT.
At 15 and 30 min, blood glucose levels were lower in
treated diabetic mice than in untreated mice. We also ob-
served a smaller AUC, suggesting a better glucose toler-
ance at least after short periods (Fig. 6A). We measured
the plasma insulin of mice in a fasted state and 30 min after
a glucose load (Fig. 6B). Of interest, we found that in vivo
GSIS was practically absent in vehicle db/dbmice, showing
a 1.04 6 0.14-fold increase over basal insulin levels,
whereas in db/db animals treated with the ERb agonist, in-
sulin secretion showed a 1.70 6 0.22-fold increase over
basal insulin. No differences were observed in the signif-
icance of insulin sensitivity between groups (Supplemen-
tary Fig. 2C).
In addition to the ERb-agonist effect on pancreatic b-cell
function, ERb activation also increased pancreatic b-cell
mass (Fig. 6C). We observed an increase in the size of the
islets, although differences between groups were not sig-
niﬁcant (P = 0.1) (Fig. 6D). We found a higher rate of b-cell
proliferation in the treated db/db mice (Fig. 6E).
In the fed state, no differences in plasma insulin or leptin
levels were found (Fig. 7A and B); however, a clear
decrease of triglyceride and glycerol plasma levels was
detected in the W10 db/dbmice (Fig. 7C and D), which was
in consonance with the weight loss observed in these
animals throughout the treatment from mainly day 8 to the
end (Fig. 7E). No changes in food intake were observed
(Supplementary Fig. 2D).
DISCUSSION
In the current study, we demonstrate the potential use of
the ERb ligand WAY200070 as an effective modulator of
insulin release and pancreatic b-cell mass, with a signiﬁ-
cant improvement in glucose homeostasis. It is clear now
that both ERa and ERb play a pivotal role in the regulation
of lipid and glucose metabolism and that a correct balance
of the ERa/ERb ratio is crucial for that (23,24). However,
most studies have focused on the role of both receptors
in the central nervous system, adipose tissue, liver, and
skeletal muscle. It has been described that the anorectic
effect of E2 seems to be mediated mainly by ERa (25,26),
although the involvement of ERb cannot be disregarded
(27). In the liver, ERa is the main regulator of hepatic in-
sulin sensitivity (28,29). In skeletal muscle, ERb is suggested
FIG. 3. In vivo administration of the ERb agonist (WAY200070) in C57BL/6 mice improved glucose homeostasis. A: IGTT performed in C57BL/6
male mice treated with W10 or vehicle (7 mice/group) during a 14-day period. The treatment resulted in better glucose sensitivity and in the
reduction of the AUC (inset). B: Insulin levels during an IGTT performed in the same group of animals. Data are provided as the fold increase in
plasma insulin (over basal) at 30 min after the glucose bolus injection. Note that there is a marked increased in in vivo insulin release in W10 mice.
C: Measurement of b-cell area (area occupied by insulin-positive cells expressed as a percentage of the total area). W10 showed a clear increase of
pancreatic b-cell mass compared with vehicle-treated mice. D: Islet size was also increased in W10 mice. E: b-Cell replication measured as the
percentage of BrdU-positive cells (7 mice/group). F: b-Cell proliferation rate in cultures of dispersed primary mouse islet cells. Cells were treated
with vehicle or WAY200070 (1, 10, and 100 nmol/L) for 2 days. BrdU was added over the same period. Data are mean 6 SE. *P< 0.05 versus vehicle
(Student t test). In F, the statistical analysis between groups was evaluated by one-way ANOVA.
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to play a repressive role on GLUT4 expression because the
ERb agonist DPN severely downregulates its expression in
ArKO (aromatase-deﬁcient) mice (30). Finally, in adipose
tissue, as is described later, ERb could have antiobesity
effects (31).
Glucose homeostasis requires a tight communication
between peripheral tissues and the pancreas, but ulti-
mately, hyperglycemia only develops when pancreatic b-cell
function fails. In previous studies, we demonstrated that
ERb regulates stimulus-secretion coupling in pancreatic
b-cells, as does E2 (11). In the present study, we conﬁrm
these results, showing that the selective ERb agonist
WAY200070 rapidly decreased KATP channel activity and
increased glucose-stimulated calcium signaling and GSIS.
Remarkably, in human islets, WAY200070 also enhanced
insulin release, with a maximal effect at a dose of 100 nmol/L.
In mice, we observed that a single injection of WAY200070
in parallel with a glucose load rapidly enhances insulin
secretion. Under fasting conditions, the selective ERb ag-
onist does not have an effect on glycemia, suggesting that
the action of this compound depends on the actual glucose
concentration and provides the possibility of glucose
normalization without the risk of hypoglycemia.
This phenomenon is mediated at least partially by ERb,
as judged from experiments performed in WT and BERKO
mice, in a process that mimics the effect of low physio-
logical concentrations of E2 (100 pmol/L–1 nmol/L), a nat-
ural ligand of ERb. However, we cannot rule out the
possibility that other estrogen receptors can provoke sim-
ilar effects. A recent report described that the activation of
G protein-coupled receptor 30 enhanced GSIS and de-
creased glucagon and somatostatin release in female hu-
man and mouse islets, although this effect is only visible
when E2 is applied at supraphysiological concentrations of
$ 100 nmol/L (32–34). ERa has been proposed to play
a signiﬁcant role in the regulation of insulin synthesis by E2
but with no effects on pancreatic b-cell mass (10). Its role
in cytoprotection has also been suggested (35).
Potential clinical implications of the insulinotropic
ERb-mediated effect. Insulin deﬁciency is the common
denominator for both type I diabetes and T2D. In the
current study, we evaluated the insulinotropic effect of an
ERb agonist by using STZ-NA diabetic mice. This model
has been reported to be useful for the assay of insulin
secretagogues (17,36,37). We observed that the ERb ago-
nist modulates insulin secretion capacity and restores
FIG. 4. Plasma hormones and lipid metabolites in C57BL/6 mice after administration of WAY200070. Plasma was collected from C57BL/6 mice
treated with the ERb agonist W10 or vehicle (6–7 mice/group) during a 14-day period, and insulin (A), leptin (B), TG (C), and glycerol (D) levels
were measured. Data are mean 6 SE. *P < 0.05 versus vehicle (Student t test). TG, triglyceride.
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FIG. 5. In vivo administration of the ERb agonist (WAY200070) improved glucose tolerance in mildly diabetic mice and restored plasma insulin levels and
pancreatic b-cell mass. A: Mild diabetes was induced by the administration of a single dose of STZ 150 mg/kg and NA 1,000 mg/kg. Ten days after the
treatment, these animals exhibited moderate hyperglycemia and impaired glucose tolerance compared with controls (8–15 mice/group). The AUC in these
mice was signiﬁcantly increased (inset). *P < 0.05 versus control (Student t test). B: At this point, 1-week treatment with the ERb agonist resulted in
a decrease of fasting glycemia as well as a better sensitivity to a glucose challenge in the W10 diabetic group compared with the vehicle-treated diabetic
group (7–8 mice/group). *P< 0.05 diabetic vehicle vs. diabetic W10; #P< 0.05 diabetic vehicle vs. control.C: Plasma insulin levels in diabetic mice treated
with WAY200070 during 1 week compared with control and nontreated diabetic mice. We observed that levels of plasma insulin in treated diabetic mice
were similar to controls; meanwhile, levels in diabetic mice were signiﬁcantly reduced (8–10 mice/group). D, E, and F: Measurement of pancreatic b-cell
mass and islet size in treated diabetic mice (5 mice/group) and b-cell replication measured as the percentage of BrdU-positive cells (5 mice/group). Data
are mean 6 SE. Statistical analysis between groups was evaluated by one-way ANOVA, with *P < 0.05 considered signiﬁcant.
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plasma insulin levels, but beyond this regulatory role of
insulin secretion, we demonstrate that a selective ERb
agonist enhances b-cell proliferation in pancreatic islets,
and thus, it could act as a regulator of b-cell growth. When
pancreatic b-cell mass was quantiﬁed in STZ-NA diabetic
mice, a clear decrease was observed compared with con-
trols. However, in the diabetic animals that were treated
with the agonist, there was a marked increase that resulted
in the recovery of b-cell mass. Of interest, in vitro studies
suggested that the ERb agonist directly stimulates b-cell
division, although the molecular basis mediating this phe-
nomenon still needs further clariﬁcation. Mechanistically,
E2 promotes islet regeneration in different animal models
of diabetes through increased b-cell proliferation (38–41).
Choi et al. (41) proposed that the E2 proliferative effect
could be mediated by the activation of the cAMP-
responsive element–binding protein, which in turn leads to
an increased level of insulin receptor substrate 2 and
pancreatic duodenal homeobox-1 levels and most proba-
bly leads to the activation of an IGF-I signaling cascade. In
addition, genistein, another natural estrogenic compound,
has been shown to improve islet b-cell proliferation, sur-
vival, and mass in diabetic mice in a process mediated by
the activation of the protein kinase A and the subsequent
phosphorylation of extracellular signal–related kinase 1/2
in b-cells (42). The authors speculated about the possibil-
ity that this signaling cascade is connected with an upre-
gulation of cyclin D1 and, thus, with the regulation of the
cell cycle machinery. Whether the ERb agonist used in this
study works through any of the presently proposed mech-
anisms remains unknown. In any case, we propose that
ERb selective agonists are considered as newcomers in the
ﬁeld of b-cell regeneration that potentially act alone or in
synergy with other known factors, such as the hepatocyte
growth factor, the glucose-dependent insulinotropic poly-
peptide, the transcription factors Pax 4, and the orphan
nuclear liver receptor homolog-1 (43).
In addition to the STZ-NA model, we studied the possi-
ble beneﬁts of ERb-agonist treatment in a different model
of diabetes, db/db mice. The administration of this drug led
to an improvement of fasting glucose levels and glucose
homeostasis, although the latter seemed to be a short-term
effect. Importantly, while no insulin release in response to
a rapid glucose stimulus was detected in the group of
db/db vehicle-treated mice, the ERb-agonist–treated group
exhibited a clear release of insulin, indicating that this
compound is able to restore the blunted ﬁrst phase of in-
sulin secretion. This phase is almost absent in individuals
with T2D (44,45). Moreover, it has been shown that there
is a delay of the ﬁrst-phase insulin secretion in BERKO
mice (46), reinforcing the importance of ERb in the main-
tenance of postprandial glucose homeostasis.
When looking at the effects of WAY200070 in STZ-NA
diabetic mice compared with db/db mice, we found that
the recovery of pancreatic b-cell function and glucose
homeostasis in the ﬁrst model was much more effective
FIG. 6. In vivo administration of the ERb agonist (WAY200070) in db/db mice enhanced ﬁrst-phase insulin secretion. A: IGTT performed in db/db
mice treated with W10 or vehicle (6–7 mice/group) during a 14-day period. B: Insulin levels during an IGTT performed in the same group of animals.
Data are provided as the fold increase in plasma insulin (over basal) at 30 min after the glucose bolus injection. C and D: Measurement of b-cell
area (area occupied by insulin-positive cells expressed as a percentage of the total area) and islet size. W10-treated db/dbmice showed an increase
of pancreatic b-cell mass compared with vehicle-treated db/db mice. E: b-Cell replication measured as the percentage of BrdU-positive cells (6–7
mice/group). Data are mean 6 SE. *P < 0.05 versus vehicle (Student t test).
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than in the second model. We hypothesized that this re-
covery is a result of the animals exhibiting a less severe
degree of diabetes in the ﬁrst case than in the second case.
Similarly, the hypoglycemic effect of E2 depends on the
severity of the diabetic condition, with no positive effects
when hyperglycemia exceeds 500 mg/dL and islet damage
is too severe (38). For these reasons, we believe that
treatment at an earlier stage of the disease would be more
effective for the db/db mice.
We also observed that the ERb-agonist treatment has
other extrapancreatic effects. It signiﬁcantly decreased
triglyceride and glycerol plasma levels in db/db mice,
which were accompanied by a reduction of body weight.
However, more information in terms of energy expenditure
FIG. 7. Plasma hormones, lipid metabolites, and increment of weight in db/db mice. Plasma was collected from W10 db/db or vehicle-treated db/db
mice after 14 days of treatment, and insulin (A), leptin (B), TG (C), and glycerol (D) levels were measured. E: Increment of weight in db/db mice
during the treatment with W10 or vehicle (6–7 mice/group). Data are mean 6 SE. *P < 0.05 versus vehicle (Student t test). TG, triglyceride.
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would largely contribute to the understanding of the role
of WAY200070 from an energetic point of view. One re-
port indicated that the administration of selective ERb
ligands prevented body weight gain in animals fed with
a high-fat diet as well as in ovariectomized mice because
of the reduction in fat mass and the increase in lean
mass (31). In contrast, a diabetogenic role for ERb has
been proposed because BERKO mice exposed to a high-
fat diet had improved whole-body insulin sensitivity and
glucose tolerance (47). In any case, the activation of
ERb demonstrates antilipogenic actions in pancreatic
b-cells (40). Its role in cytoprotection has also been
suggested (35).
In summary, we propose that an ERb agonist could act
as a regulator of pancreatic b-cell growth and that it pro-
motes an increase of b-cell mass under pathological con-
ditions. In addition, by using different experimental animal
models of diabetes, we demonstrate the capacity of this
agonist to normalize fasting glucose levels, to enhance
endogenous insulin secretion, and to improve glucose
homeostasis. Therefore, ERb agonists may be useful new
drugs for the treatment of T2D.
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